Project Grant W81XWH2110719

Myogene Bio LLC received a $499,300 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective September 1, 2025 through July 31, 2028. The award supports the advancement of manufacturing and analytical testing capabilities for a dual adeno-associated virus (AAV) vector gene editing therapy targeting Duchenne muscular dystrophy (DMD). Under this...

The National Heart, Lung, and Blood Institute (NHLBI) awarded Novomedix LLC a $306,872 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop novel oral small molecule therapeutics for the treatment of progressive pulmonary fibrosis, including idiopathic pulmonary fibrosis (IPF). The goal is to create a safer and more effective therapy compared to the currently approved drugs, which only slow disease progression and have significant side effects. Novomedix will...

The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $295,923 Project Grant to Kinetiq Therapeutics LLC to conduct preclinical efficacy studies of a subcutaneous enzyme therapy for Fabry disease. The proposed therapy, named BRYSQ, aims to transform the current standard of care by providing a convenient, self-administered treatment that could improve patient quality of life, reduce hospital use, and lower treatment costs compared to the...

The University of Florida Division of Sponsored Research received a $536,800 Project Grant from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The grant will fund a 3-year exploratory clinical trial to investigate the potential of the drug tadalafil, combined with structured exercise training, to improve muscle pathophysiology and function in individuals with Duchenne...

Grant Award Summary Advertent Biotherapeutics, Inc. received a $1.29 million Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), effective July 1, 2025 through June 30, 2027. The award supports the development of ADA011, a transformative growth factor beta-1/3 (TGF-β1/3) inhibitor biotherapeutic candidate designed to prevent muscle fatty degeneration and...

Federal Grant Award Summary Nostopharma LLC received a $815,584 Project Grant award from the National Center for Advancing Translational Sciences (NCATS), CFDA 93.350, effective July 3, 2025 through June 30, 2027. The award funds preclinical proof-of-concept research for a novel localized drug delivery treatment addressing Fibrodysplasia Ossificans Progressiva (FOP), an ultrarare genetic disease affecting approximately 1 in 1.5-2.0 million live births. The primary deliverable is the...

This $563,484.00 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by Duke University to regulate skeletal muscle fibrosis in Duchenne muscular dystrophy. The two-year award, effective June 1, 2024 through May 31, 2026, will enable Duke University's research team to advance understanding and potential treatments for this debilitating neuromuscular disorder affecting military service members and...

This $516,000 Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program will support the development of injectable cellulose-based hydrogels for soft tissue bulking from July 1, 2022 to June 30, 2024. The Research Foundation of the City University of New York, in partnership with the City University of New York, will engineer a stable yet reversible injectable soft tissue filler material derived from plant polysaccharides like cellulose. If successful,...

Spinethera Inc. was awarded a $4,970,750.90 Project Grant from the Defense Health Agency to conduct GLP toxicology testing and Phase 2/3 development for a nonopioid, injectable drug product for the treatment of lumbosacral radiculopathy, also known as sciatica. This work will be carried out under the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to transform military and public health care through innovative and impactful investigations....

Nostopharma LLC was awarded a $256,000 Small Business Technology Transfer Phase I Project Grant from the National Science Foundation to develop a sustained-release, biodegradable nanoparticle drug delivery system for treatment of soft tissue trauma complications. Funded under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084), the 12-month project beginning March 1, 2022 aims to demonstrate in vitro and in vivo feasibility of modulating the ectopic bone microenvironment...